Patients with chronic cough reported autonomic symptoms with substantially increased frequency and severity when compared with a healthy control population.
A study revealed that chronic cough, thought to be a neuronal hypersensitivity disorder, is linked with more frequent and severe autonomic symptoms. The results were published in ERJ Open Research.
This finding is in accordance with previous observations that patients with similar neuronal hypersensitivity disorders experience increased autonomic symptoms.
Patients with chronic cough can cough upwards of thousands of times a day. Coughing episodes stimulate the autonomic nervous system, which results in raised blood pressure and heart rate. Protracted coughing can lead to a desensitization of the autonomic system, which can subsequently lead to sympathetic dominance, autonomic imbalance, and autonomic dysfunction.
Although previous associations have been found between autonomic dysfunction and conditions characterized by neuronal/visceral hypersensitivity such as irritable bowel syndrome, fibromyalgia, and complex regional pain syndrome, this is the first study of its kind to investigate whether patients with chronic cough experience increased autonomic symptoms, the authors said.
In their study, investigators recruited 96 patients with chronic cough and 76 healthy controls from a hospital in Manchester in the United Kingdom. Participants completed the Composite Autonomic Symptom Score (COMPASS) 31 autonomic symptom questionnaire to measure self-reported autonomic symptoms and functions and results were compared between the patient population and the age- and gender-matched healthy control population.
The COMPASS questionnaire scored symptoms across 6 areas: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor.
Participants also completed the Cough Quality of Life Questionnaire (CQLQ) to measure the impact of cough on daily life, and a cough severity visual analogue (VAS) scale to measure cough severity. Associations between the COMPASS questionnaire and the 2 subsequent measurement instruments were observed.
Findings showed:
The study findings indicated that patients with chronic cough experienced autonomic symptoms with substantially increased frequency and severity than healthy volunteers, suggesting that this population may be subject to autonomic dysfunction. These symptoms were predominantly observed in parasympathetically mediated systems. Whether a patient’s cough causes this effect, or if both the cough and dysfunction are part of a wider vagal pathology, is unclear and requires further investigation, the authors said.
Reference
Dockry RJ, Farrelly CL, Mitchell J, Corfield DR, Smith JA. Chronic cough is associated with increased reporting of autonomic symptoms. ERJ Open Res. 2021;7(3):00105-2021. doi:10.1183/23120541.00105-2021
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More